Physician profile
Steven Ramm
NPI 1801876628
$13,725.82
in general payments reported to CMS, 2019-2025
44 companies · $3,390 in 2025
The $3,390 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,791 · 2022: $2,360 · 2023: $2,915 · 2024: $3,270 · 2025: $3,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,499 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,499.47 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,183.78 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,492.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,276.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,202.43 | 2021-2025 | |
| Novo Nordisk INC | $1,200.16 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,088.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $858.31 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $626.28 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $570.45 | 2022-2025 | Rexulti |
| Abbott Laboratories | $489.57 | 2022-2025 | Freestyle Libre |
| Exact Sciences Corporation | $265.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $212.20 | 2021-2024 | |
| Axsome Therapeutics, INC. | $191.61 | 2023-2025 | Auvelity, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $189.34 | 2021-2022 | |
| Amgen INC. | $154.38 | 2022-2025 | Otezla, Repatha, Evenity |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ramm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.